Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665206 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by Vivace Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 336
- Enrollment target
- 12
- Study locations
NCT04665206 is a Phase 1 study of Solid Tumor, Adult and NSCLC that is actively recruiting participants, run by Vivace Therapeutics. The registered enrollment target is 336 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (81% higher). The trial reports 12 study locations across 9 states.
The verdict
NCT04665206, a Phase 1 study of Solid Tumor, Adult and NSCLC, is actively recruiting participants, sponsored by Vivace Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 336 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG VT3989
- DRUG Nivolumab & Ipilimumab
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Victoria
- Monash Health - Clayton
- Peter MacCullum Cancer Centre - Melbourne
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Medical Center - Chicago
Minnesota
- M Health Fairview University of Minnesota Medical Center - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Virginia
- Virginia Cancer Specialists, PC - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2027-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04665206
The ClinicalTrials.gov registry entry for NCT04665206 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (81% higher). The listed sponsor is Vivace Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.
NCT04665206 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, Texas, Victoria.
Frequently Asked Questions
What is clinical trial NCT04665206 about?
NCT04665206 is a clinical study titled "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors". This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no...
What is the current status of trial NCT04665206?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2021-03-24. Estimated completion is 2027-06-02.
What conditions does trial NCT04665206 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, NSCLC, Mesothelioma.
What interventions are being tested in trial NCT04665206?
The interventions under investigation include: Osimertinib (DRUG), VT3989 (DRUG), Nivolumab & Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04665206?
This trial is sponsored by Vivace Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04665206 being conducted?
This trial has 12 study locations across California, Illinois, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.